SCHEDULE 13G: Cormorant Asset Management Discloses Significant 7.33% Stake in CARGO Therapeutics

Cormorant Asset Management, LP and Bihua Chen have disclosed a 7.33% beneficial ownership stake in CARGO Therapeutics, Inc., holding 3,381,277 shares of common stock.

Summary

• Cormorant Asset Management, LP and Bihua Chen have filed a Schedule 13G, disclosing their beneficial ownership in CARGO Therapeutics, Inc.
• The reporting persons collectively beneficially own 3,381,277 shares of CARGO Therapeutics' common stock.
• This ownership represents 7.33% of the company's outstanding common stock.
• The shares are held with shared voting power and shared dispositive power.
• The percentage is calculated based on 46,113,353 shares of common stock outstanding as of May 2, 2025, as reported in CARGO Therapeutics' Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing itself is a factual disclosure, but the acquisition of a significant stake by a reputable institutional investor is generally perceived as a positive signal for the company, indicating investor confidence.

Positives

• The disclosure of a significant stake by an institutional investor like Cormorant Asset Management may signal confidence in CARGO Therapeutics' future prospects.
• Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, holds more than 5% of the shares, indicating a substantial commitment from a specialized healthcare investor.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from CARGO Therapeutics, Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• Bihua Chen, Managing Member of Cormorant Asset Management, LP, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates a significant investment by a specialized healthcare asset manager in a therapeutics company, aligning with broader trends of institutional interest in the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence in the company's valuation and future prospects, which could positively influence share price.

Next Steps

• Cormorant Asset Management, LP and Bihua Chen will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership or the purpose of their investment.

Key Dates

Keywords

CARGO Therapeutics, Cormorant Asset Management, Bihua Chen, Schedule 13G, beneficial ownership, institutional investment, common stock, SEC filing